跳至主要内容
临床试验/NCT06729554
NCT06729554招募中不适用

Education & Care in RARE - Efficacy of Targeted Psychoeducational Intervention to Improve Knowledge About Rare Diseases and to Promote Mental Health Among Pediatric Rare Disease Patients

Medical University of Vienna12 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2024年12月15日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
100
试验地点
12
主要终点
Rare Disease Specific Self-Rating Scale

研究概览

简要总结

"Rare Diseases" is an umbrella term including more than 8.000 different diseases which individually affect only a small percentage of people. Rare diseases predominantly affect children and adolescents and are associated with high medical and psychosocial burden of disease.

The investigators invented Education & Care in RARE - a short-term, structured, resource-oriented and child-friendly psychoeducation program for children and adolescents with rare diseases.

This study is a prospective, multicenter, randomized and controlled study with a waiting list. Aim of the study is to investigate the efficacy of Education & Care in RARE on knowledge about rare diseases and on mental health well-being in pediatric rare disease patients, compared to a control group.

In this study participants are randomized in an intervention group and a waiting list control group. Both study groups thus receive the psychoeducation with Education & Care in RARE and complete the identical questionnaires. Compared to the Intervention group, the waiting list control group receives the intervention with a time delay (8-12 weeks later) and has one additional appointment for questionnaire evaluation before start of the psychoeducation.

详细描述

  1. Background 1.1. Rare diseases Rare diseases are defined as serious diseases which affect only a very small number of people compared to the general population. The more than 8.000 different rare diseases most often affect children and encompass an enormous heterogenous clinical spectrum associated mostly with a chronic or progressive disease course. In addition to the clinical and economic burden of a chronic disease, patients with rare diseases faces also the "rare disease burden" which describes associated problems caused by rarity of the disease. 1-3While advances in rare disease research have significantly improved the diagnostic and therapeutic strategies in rare diseases, psychosocial care is still not part of routine care in rare diseases. 4 1.2. Own previous work The investigator team is highly experienced in both, the molecular characterization 5-16 and the clinical care 17-21 of rare and ultra-rare diseases and in psychosocial care 22-27 of pediatric patients in acute and chronic stress situations. Based on this experience the investigators developed a psycho-educational intervention program for children and adolescents affected by a rare disease named "Education & Care in RARE" Figure 1.

Education & Care in RARE (https://www.youtube.com/watch?v=R3fr-q-6JIw) is a short-term, structured, resource-oriented and child-friendly psychoeducation program for children and adolescents with rare diseases. It promotes knowledge and competence on rare diseases in children in order to reduce the psychosocial rare disease burden and to improve individual self-competence in managing the rare disease and to improve their quality of life. Education & Care in RARE can be used for all pediatric rare diseases. This has the great advantage that users only need to be trained in the use of one program. Figure 1 Education & Care in RARE is used during clinical care at the outpatient clinic for clinical genetics, Department of Pediatrics and Adolescent Medicine, Division of Pediatric Pulmonology, Allergology and Endocrinology. Education & Care in RARE is currently not available in routine care outside of this specialized outpatient clinic. Affected children who have completed Education & Care in RARE during clinical care, have rated this as a very helpful and supportive program. To date, there has been no study on the effectiveness of Education & Care in RARE. 2. Aims and hypotheses of the study 2.1. Aims This study aims to investigate the efficacy of Education & Care in RARE on knowledge about rare diseases and on mental health well-being in pediatric rare disease patients.

As a primary objective the investigators will evaluate

> The effect of Education & Care in RARE on participants' self-rating scales regarding knowledge about rare diseases and well-being, compared to a control group.

As secondary objectives the investigators will evaluate

  • The effect of Education & Care in RARE on expert-rating scales regarding participants' knowledge about rare diseases and competences to cope with rare-disease specific challenges, compared to a control group.
  • The effect of Education & Care in RARE on generic Quality of Life and mental health well-being questionnaires, compared to a control group.
  • Moderating effects (such as age, rare disease diagnosis, additional diagnosis) on the efficacy of Education & Care in RARE
  • The long-term effect of Education & Care in RARE on participants' knowledge about rare diseases and on mental health well-being.
  • Differences in Quality of Life and mental health well-being of children and adolescents with rare disease, compared to norm data.
  • Since this is the first study on Education & Care in RARE, we will also evaluate the satisfaction with the intervention for the intervention groups and for the applying experts.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
5 Years 至 20 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Children and adolescents with a confirmed diagnosis of a rare disease with
  • Age 5-20 years, corresponding to a developmental age of 5-18 years
  • Existing medical care at a participating study center because of the rare disease
  • Voluntary participation and informed consent
  • Ability to complete the questionnaires
  • Ability to actively participate the intervention (psychoeducation)

排除标准

  • Moderate or severe cognitive impairment
  • Simultaneous admission of the child / adolescent to a setting with high-frequency psychotherapeutic intervention (e.g. admission to psychosomatic medicine, child and adolescent psychiatry)
  • No informed consent
  • Language barrier of the child / adolescent
  • Assumption that compliance is too low to attend all study appointments

研究组 & 干预措施

Intervention Group (IG)

Experimental

Participants are randomized in an intervention group (IG) and a waiting list control group (WLG). The IG receive the intervention with Education & Care in RARE (all children) and complete the identical questionnaires (all children and their legal guardians) immedeately after inclusion.

干预措施: Education & Care in RARE (Other)

Waiting List Control Group (WLG)

Active Comparator

Compared to the IG, the WLG receives the intervention with Education & Care in RARE with a time delay (8-12 weeks later) and has one additional appointment for questionnaire evaluation before start of the intervention.

干预措施: Education & Care in RARE (Other)

结局指标

主要结局

Rare Disease Specific Self-Rating Scale

时间窗: IG: T0 (at inclusion), T1 (after intervention), T2 (3 to 6 months after T1); WLG: T0 (at inclusion), T1 (2-3 months after T0), T2 (after intervention), T3 (3 to 6 months after T2)

Description: The Rare Disease Specific Self-Rating Scale is defined as primary outcome measurement of this study. The Rare Disease Specific Self-Rating Scale provides 10 items to assess rare disease specific knowledge and well-being in children and adolescents and uses a Six-Point Smiley Faces Likert Scale as a global subjective outcome scale for children assessment. For the primary hypothesis, a mean value of the 10 items is computed for each participant. The Rare Disease Specific Self-Rating Scale covers specific topics on Rare Diseases which are not covered by the generic research instruments of this study. Outcome Measurements: Knowledge about rare diseases; Well-being Items; Scale level: 10 items; 6-Point Smiley Faces Likert Scale; sum total score 10-60;

次要结局

  • Rare Diseases Specific Expert-Rating Scale(IG: T0 (at inclusion), T1 (after intervention), T2 (3 to 6 months after T1); WLG: T0 (at inclusion), T1 (2-3 months after T0), T2 (after intervention), T3 (3 to 6 months after T2))
  • SDQ Strengths and Difficulties Questionnaire self-report(IG: T0 (at inclusion), T1 (after intervention), T2 (3 to 6 months after T1); WLG: T0 (at inclusion), T1 (2-3 months after T0), T2 (after intervention), T3 (3 to 6 months after T2))
  • SDQ Strengths and Difficulties Questionnaire, third- party-report(IG: T0 (at inclusion), T2 (3 to 6 months after T1, T1 is defined as time point immideately after intervention); WLG: T0 (at inclusion), T1 (2-3 months after T0), T3 (3 to 6 months after T2, T2 is defined as time point immideately after intervention))
  • KINDL self-report(IG: T0 (at inclusion), T1 (after intervention), T2 (3 to 6 months after T1); WLG: T0 (at inclusion), T1 (2-3 months after T0), T2 (after intervention), T3 (3 to 6 months after T2))
  • KINDL third-party-report(IG: T0 (at inclusion), T2 (3 to 6 months after T1, T1 is defined as time point immideately after intervention); WLG: T0 (at inclusion), T1 (2-3 months after T0), T3 (3 to 6 months after T2, T2is defined as time point immideately after intervention))
  • Patients' evaluation of the Education & Care in RARE Program(IG: T1 (after intervention); WLG T2 (after intervention))
  • Expert Evaluation of the Education & Care in RARE program(IG: T1 (after intervention); WLG T2 (after intervention))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Julia Vodopiutz

MD ap Prof

Medical University of Vienna

研究点 (12)

Loading locations...

相似试验